Bordeaux

• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activ … Ended
  2022-500116-18-00 3 2023-01-09 Advanced Solid Tumors
• Relatlimab + Nivolumab in Pediatric and Young Adult Lymphomas (RELATIVITY-069) Ended
  2023-503715-14-00 9 2022-12-29 Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lym
• An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s dis … Ended
  2022-500424-30-00 4 2022-12-28 Parkinson’s disease
• An Open-Label Extension Study for Patients who Previously Completed Study ISEE2008 (GATHER2) Ended
  2024-515185-13-00 5 2022-12-21 geographic atrophy
• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended
  2023-508528-36-00 5 2022-12-16 Resected squamous cell carcinoma of the head and neck
• A study to test whether BI 907828 helps people with cancer in the biliary tract, pancreas, lung, or bladder Ended
  2023-506369-79-00 4 2022-11-30 Pancreatic ductal adenocarcinoma
• MYOCIT - Baricitinib in the treatment of new-onset juvenile dermatomyositis: a phase II trial Ended
  2024-513651-32-00 4 2022-11-10 Juvenile Dermatomyositis
• A study to test the safety of MK-1654 and how well MK-1654 works in healthy infants Ended
  2022-500350-42-01 10 2022-11-07 Prevention of RSV
• VISIONARY Trial: Phase 3 Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) Ended
  2022-500079-30-00 5 2022-11-03 IgA Nephropathy
• Study to see how safe is TNG908 at different doses in patients with solid tumors that have a gene called MTAP missing Ended
  2024-511976-34-00 7 2022-10-31 "Ph1: •Locally advanced (LA) or metastatic MTAP-deleted (met.MTAP-del.
• A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti–LAG-3) and INCAGN02390 (Anti–TI … Ended
  2023-504270-38-00 4 2022-10-18 In participants with PD-L1–positive and systemic therapy–naive R/M SCC
• A Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Ewing's Sarcoma Ended
  2023-506772-28-00 4 2022-10-07 Ewings Sarcoma
• Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended
  2023-505458-16-00 5 2022-09-13 Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpressio
• A Study of SGN-B7H4V in Advanced Solid Tumors Ended
  2023-503389-22-00 1 2022-08-31 Fallopian tube cancer
• Efficacy and Safety of AXL-Inhibitor bemcentinib for the Treatment of Moderate COVID-19 (AXL-SolidAct) Ended
  2022-500363-12-00 4 2022-08-24 SARS CoV-2 (COVID-19)
• Cohort study of human mpox virus disease Ended
  2022-501132-42-00 6 2022-08-02 Monkeypox virus disease
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of RO7303509 in Patients with Systemic Sclero … Ended
  2022-502981-26-00 3 2022-06-27 Systemic Sclerosis
• PhagoDAIR I : A Pilot, Multicenter, Randomized, Non Comparative, Double-Blind Study of Phage Therapy in Patients with Hip or Knee Prosthetic … Ended
  2024-516207-17-00 4 2022-06-15 knee or hip prosthetic joint infection (PJI) due to Staphylococcus aur
• A study in patients with different types of advanced cancer (solid tumors) to test different doses of BI 907828 (brigimadlin) in combination … Ended
  2024-511352-41-00 3 2022-06-13 advanced solid tumors
• Iron chelation in the prevention of secondary degeneration after stroke Ended
  2024-514230-20-00 4 2022-06-08 Stroke
• Randomized multicenter double-blind controlled trial comparing anakinra to prednisone for gout flare in patients with chronic kidney disease … Ended
  2024-514347-28-00 5 2022-06-02 Men and women over 18 years of age with renal failure renal failure st
• Evaluation of MEpolizumab-based regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Eosinophilic … Ended
  2024-513653-75-00 5 2022-05-30 Eosinophilic granulomatosis with polyangiitis (EGPA), formerly called
• PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCL … Ended
  2024-511975-14-00 9 2022-05-26 recurrent/refractory Ewing sarcoma

Showing 961–984 of 1,109 trials